Biogen gains as Medicare to cover new Alzheimer’s drug with full FDA approval

American Hospital Association Holds Annual Membership Meeting

Chip Somodevilla/Getty Images News

Biogen (NASDAQ:BIIB) shares bounced back Wednesday after a top Medicare official said that the agency would cover the new Alzheimer's treatment Leqembi (lecanemab) in the event of full US FDA approval.

Testifying before the House Subcommittee

Recommended For You

Related Stocks

SymbolLast Price% Chg
BIIB
--
ESALF
--
ESAIY
--